Poseida Therapeutics (NASDAQ:PSTX) Earns Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Poseida Therapeutics (NASDAQ:PSTX - Free Report) in a research report released on Wednesday morning, Benzinga reports. HC Wainwright currently has a $20.00 price objective on the stock.

Poseida Therapeutics Stock Up 3.0 %

Shares of NASDAQ PSTX traded up $0.09 during midday trading on Wednesday, hitting $3.06. The company's stock had a trading volume of 485,894 shares, compared to its average volume of 696,043. The business's fifty day simple moving average is $2.79 and its two-hundred day simple moving average is $3.02. The company has a debt-to-equity ratio of 0.69, a current ratio of 2.56 and a quick ratio of 2.56. Poseida Therapeutics has a 1 year low of $1.54 and a 1 year high of $4.27. The firm has a market capitalization of $296.70 million, a price-to-earnings ratio of -2.57 and a beta of 0.46.

Poseida Therapeutics (NASDAQ:PSTX - Get Free Report) last posted its quarterly earnings data on Thursday, March 7th. The company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.09. Poseida Therapeutics had a negative net margin of 131.95% and a negative return on equity of 97.36%. The business had revenue of $25.00 million during the quarter, compared to analyst estimates of $12.50 million. On average, equities analysts predict that Poseida Therapeutics will post -1.66 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in PSTX. Allspring Global Investments Holdings LLC purchased a new position in Poseida Therapeutics in the third quarter worth approximately $29,000. Bayesian Capital Management LP acquired a new stake in Poseida Therapeutics during the first quarter worth approximately $33,000. Dynamic Technology Lab Private Ltd acquired a new stake in Poseida Therapeutics during the fourth quarter worth approximately $36,000. Tower Research Capital LLC TRC raised its holdings in Poseida Therapeutics by 110.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 10,679 shares of the company's stock worth $36,000 after purchasing an additional 5,606 shares in the last quarter. Finally, Keystone Financial Group acquired a new stake in Poseida Therapeutics during the third quarter worth approximately $36,000. Hedge funds and other institutional investors own 46.87% of the company's stock.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.